News

Takeda said that TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20

Par Pharma has posted a net income of $30.53m for the third quarter 2010, compared to $26.34m for the comparable period in 2009. Operating income was $40.61m, compared

Egberts will replace current CEO Simon Sturge, who will leave the company as per 1 January 2011. Egberts is expected to immediately start working together with Sturge until

Affymax CEO Arlene Morris said that the Therapeutic Discovery Project empowers small biotech companies, like Affymax, by providing needed capital to support breakthrough medical discovery, innovation and job

The grants are related to four of Lipocine’s development programs in hormone replacement therapy, high-risk pregnancy support, oral treatment of progressive glioblastoma multiforme and opioid resistant cough in

The grant, which targets therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or to treat chronic

Perrigo has posted a net income of $74.38m for the first quarter 2010, or $0.80 per diluted share, compared to $51.86m, or $0.56 per diluted share, for the

This pharmaceutical optimisation followed the demonstration of safety and the presumption of efficacy of oral doses as high as 4mg of inecalcitol per day in a Phase IIa

Data from Phase I/II study showed that treatment with Everolimus was associated with a significant reduction in primary SEGA volume at six months relative to baseline on independent